Shots:

• Mitsubishi Tanabe Pharma (MTPA) enters into a collaboration with Massachusetts General Hospital (MGH) Neurological Clinical Research Institute (NCRI) to conduct ALS biomarker study for identification of biomarkers in patients with amyotrophic lateral sclerosis (ALS)
• The ALS biomarker study will evaluate 4 biomarkers enrolling 200 patients receiving Radicava (edaravone) for 24wks. across 40 sites and will be conducted & sponsored by MGH & MTPA respectively with its expected interim analyses in H2’19
• RADICAVA (edaravone- IV) is a neuroprotective agent indicated for the treatment of ALS and has received approval in the US- Japan and South Korea in May’17- Jun’15 & Dec’15 respectively for ALS

Ref: Mitsubishi Tanabe Pharma | Image: MGH